Previous 10 | Next 10 |
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and twelve months ended December 31, 2021. 2021 Highligh...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 8, 2022. The co...
Disior advances Paragon 28’s SMART 28™ strategy, providing a comprehensive 3D analytics and pre-operative planning platform, and will immediately accelerate internal research programs Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28ȁ...
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended Decembe...
Paragon 28 (NYSE:FNA) perks up 1.4% premarket after announcing that the FDA has given 501(k) marketing clearance to its R3ACT Stabilization System. The R3ACT Stabilization System is expected to commercially launch in early 2022. The addition of the R3ACT Stabilization Syst...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its R3ACT™ Stabilization ...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will virtually present at the 24 th Annual Needham Gro...
Paragon 28, Inc. (NYSE: FNA ) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufa...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of B. Kristine Johnson and Kristina Wright to the Board of Directors, effective December 1, 2021. ...
Paragon 28 (NYSE:FNA): Q3 Non-GAAP EPS of -$0.12 misses by $0.05. Revenue of $35.85M (+18.5% Y/Y) beats by $0.91M. Press Release For further details see: Paragon 28 EPS misses by $0.05, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company’s managem...
2024-06-11 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-11 02:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...